We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Inflammatory Markers in Pregnant Women Destined to Develop Preeclampsia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 6, 2011
Last Update Posted: July 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Oslo University Hospital
The purpose of this study is to assess the predictive role of serum inflammatory markers in pregnant women who subsequently develop preeclampsia.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Biospecimen Retention:   Samples Without DNA

Enrollment: 129
Study Start Date: January 1999
Study Completion Date: June 2011
Primary Completion Date: May 2004 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 43 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Case-control study consisting of 43 women developping preeclampsia and 86 women not developping this disorder. All were of Caucasian origin and were nulliparous.

Inclusion Criteria:

  • caucasian,
  • nulliparous

Exclusion Criteria:

  • preexisting cardiovascular diseases,
  • diabetes,
  • hypertension,
  • inflammatory bowel diseases,
  • serious organ diseases, and
  • development of separate gestational diabetes and/or hypertension.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Oslo University Hospital, Department of Medical Biochemistry
ClinicalTrials.gov Identifier: NCT01388283     History of Changes
Other Study ID Numbers: INMARPE11
First Submitted: June 30, 2011
First Posted: July 6, 2011
Last Update Posted: July 6, 2011
Last Verified: June 2011

Keywords provided by Oslo University Hospital:
prognostic marker

Additional relevant MeSH terms:
Hypertension, Pregnancy-Induced
Pregnancy Complications